(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

LINQURE

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

LINQURE

ST13

US500000090736220

Class

5, 42, 44

Filing

90736220

Registration

7376828

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

38

Latest update

06/12/2025

Trademark type

Word

Nice classes

5, 42, 44

Filing date

05/26/2021

Registration date

05/07/2024

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

05/07/2024

Last transaction

06/12/2025

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use, Foreign priority

Drawing code

4

Owner type

26

Owner location

AMSTERDAM, NL

Examiner

CHADAB, SETH

Law office

L40

Current location

FILE REPOSITORY (FRANCONIA)

Holders and representatives

Holders

UNIQURE BIOPHARMA B.V.
uniQure IP B.V.

Representatives

Julianne Abelman ABELMAN LAW PLLC

Technical classification

Nice Classes

Class 5Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Medicinal preparations for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseasesviral systemsgene therapy systemsnucleic acid delivery systemsviral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors or nucleic acid delivery vectors; Viral systemsgene therapy systemsnucleic acid delivery systems for medical purposesmedicines for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid based therapygene therapycell therapygene diagnosis and gene testing

Class 42

Researchproduct development and consultancy in the field of biotechnologybiologicsmedical sciencechemistry and biochemistry; Research and product development in the field of pharmaceuticspharmaceutics in the field of gene therapy

Class 44

Gene and nucleic acid deliverygene and nucleic acid transfergene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesinflammatory and auto-immune diseasesvascular disordersinherited disordersgenetic disorders and single gene disorders; Consultancy in the field of pharmaceuticspharmaceutics in the field of gene therapy

Publications

History of USPTO decisions and trademark events.

38 publications found

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

06/11/2025

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

06/04/2025

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

06/04/2025

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

06/04/2025

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

06/04/2025

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

06/04/2025

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

06/04/2025

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

06/04/2025

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

05/07/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

05/07/2024

CHPB

POST PUBLICATION AMENDMENT - ENTERED

01/27/2023

ETOP

EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED

01/26/2023

APET

ASSIGNED TO PETITION STAFF

01/25/2023

EPPA

TEAS POST PUBLICATION AMENDMENT RECEIVED

01/12/2023

ETOF

EXTENSION OF TIME TO OPPOSE RECEIVED

08/18/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

07/20/2022

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

07/20/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

07/20/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

07/20/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

07/19/2022

PUBO

PUBLISHED FOR OPPOSITION

07/19/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

06/29/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/13/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/31/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/31/2022

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

05/31/2022

ALIE

ASSIGNED TO LIE

05/28/2022

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

05/22/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

05/22/2022

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

05/22/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

05/22/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

05/22/2022

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

02/10/2022

GNSL

LETTER OF SUSPENSION E-MAILED

02/10/2022

CNSL

SUSPENSION LETTER WRITTEN

02/10/2022

DOCK

ASSIGNED TO EXAMINER

02/08/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/20/2021

NWAP

NEW APPLICATION ENTERED

05/29/2021

Continuous trademark protection

Get notified about every new filing that threatens LINQURE or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.